GSK256066

• CAT Number: I007091
• CAS Number: 801312-28-7
• Molecular Formula: C27H26N4O5S
• Molecular Weight: 518.59
• Purity: ≥95%
• Synonyms: GSK256066; GSK-256066; GSK 256066.;6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide
• Target: Phosphodiesterase (PDE)
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term or -20 °C for long term
• IC50: 3.2 pM
• IUPAC Name: 6-[3-(dimethylcarbamoyl)phenyl]sulfonyl-4-(3-methoxyanilino)-8-methylquinoline-3-carboxamide
• InChI: InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)
• InChIKey: JFHROPTYMMSOLG-UHFFFAOYSA-N
• SMILES: CC1=CC(=CC2=C(C(=CN=C12)C(=O)N)NC3=CC(=CC=C3)OC)S(=O)(=O)C4=CC=CC(=C4)C(=O)N(C)C

GSK256066（Cat No.:I007091）is a selective and potent inhibitor of the protein kinase enzyme, CSF1R (colony-stimulating factor 1 receptor). This receptor is involved in the regulation of monocytes and macrophages, which play a role in inflammation and immune responses. GSK256066 has been investigated for its potential in treating inflammatory diseases, such as rheumatoid arthritis and certain cancers, by modulating the immune system. By inhibiting CSF1R, it can reduce the recruitment and activation of macrophages, which may help control disease progression. Further clinical studies are needed to evaluate its safety, efficacy, and therapeutic applications.